| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Aysun Kalenderoğlu, Mustafa Çeli. [Augmentation of Clozapine With Paliperidone in Schizophrenia Patients With Partial Response to Treatment: A Case Series]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 27. issue 1. 2017-03-27. PMID:27369686. |
in this case series treatments of 5 schizophrenia patients who still had symptoms despite clozapine treatment were augmented with paliperidone during 6 months of follow up. |
2017-03-27 |
2023-08-13 |
Not clear |
| Aysun Kalenderoğlu, Mustafa Çeli. [Augmentation of Clozapine With Paliperidone in Schizophrenia Patients With Partial Response to Treatment: A Case Series]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 27. issue 1. 2017-03-27. PMID:27369686. |
evaluation of paliperidone's effects on negative symptoms in schizophrenia patients with partial response to clozapine treatment using randomized, placebo controlled studies may provide an important treatment choice. |
2017-03-27 |
2023-08-13 |
Not clear |
| Jadwiga Piwowarska, Maria Radziwoń-Zaleska, Martyna Dmochowska, Ewa Szepietowska, Halina Matsumoto, Grażyna Sygitowicz, Andrzej Pilc, Jacek Łukaszkiewic. The usefulness of monitored therapy using Clozapine concentration in the blood serum for determining drug dose in Polish schizophrenic patients. Pharmacological reports : PR. vol 68. issue 6. 2017-03-23. PMID:27588387. |
the aim of the study is to evaluate the advisability of systematic monitoring of clozapine (clo) concentration in serum during treatment of schizophrenia in polish psychiatric patients. |
2017-03-23 |
2023-08-13 |
Not clear |
| Petru Ifteni, Andreea S Szalontay, Andreea Teodoresc. Reducing Restraint With Clozapine in Involuntarily Admitted Patients With Schizophrenia. American journal of therapeutics. vol 24. issue 2. 2017-03-14. PMID:27984264. |
reducing restraint with clozapine in involuntarily admitted patients with schizophrenia. |
2017-03-14 |
2023-08-13 |
Not clear |
| Shyam Sundar Arumugham, Jagadisha Thirthalli, Chittaranjan Andrad. Efficacy and safety of combining clozapine with electrical or magnetic brain stimulation in treatment-refractory schizophrenia. Expert review of clinical pharmacology. vol 9. issue 9. 2017-03-10. PMID:27322602. |
efficacy and safety of combining clozapine with electrical or magnetic brain stimulation in treatment-refractory schizophrenia. |
2017-03-10 |
2023-08-13 |
Not clear |
| Shyam Sundar Arumugham, Jagadisha Thirthalli, Chittaranjan Andrad. Efficacy and safety of combining clozapine with electrical or magnetic brain stimulation in treatment-refractory schizophrenia. Expert review of clinical pharmacology. vol 9. issue 9. 2017-03-10. PMID:27322602. |
a substantial proportion (40-70%) of patients with treatment-resistant schizophrenia experience persistent symptoms despite an adequate clozapine trial. |
2017-03-10 |
2023-08-13 |
Not clear |
| E Trinczek, M Heinzel-Gutenbrunner, M Haberhausen, C J Bachman. Time to Initiation of Clozapine Treatment in Children and Adolescents with Early-Onset Schizophrenia. Pharmacopsychiatry. vol 49. issue 6. 2017-03-09. PMID:27737473. |
time to initiation of clozapine treatment in children and adolescents with early-onset schizophrenia. |
2017-03-09 |
2023-08-13 |
Not clear |
| Masahiko Kawano, Hidehiro Oshibuchi, Takaaki Kawano, Hiroyuki Muraoka, Takahiro Tsutsumi, Makiko Yamada, Ken Inada, Jun Ishigook. Dopamine dynamics during emotional cognitive processing: Implications of the specific actions of clozapine compared with haloperidol. European journal of pharmacology. vol 781. 2017-03-08. PMID:27085900. |
clozapine has improved efficacy relative to typical antipsychotics in schizophrenia treatment, particularly regarding emotional symptoms. |
2017-03-08 |
2023-08-13 |
rat |
| Masahiko Kawano, Hidehiro Oshibuchi, Takaaki Kawano, Hiroyuki Muraoka, Takahiro Tsutsumi, Makiko Yamada, Ken Inada, Jun Ishigook. Dopamine dynamics during emotional cognitive processing: Implications of the specific actions of clozapine compared with haloperidol. European journal of pharmacology. vol 781. 2017-03-08. PMID:27085900. |
however, the specific dopaminergic state-dependent action of clozapine on both basal dopamine levels and stress-induced dopamine release may be the underlying mechanism for its superior clinical effect on emotional cognitive processing in patients with schizophrenia. |
2017-03-08 |
2023-08-13 |
rat |
| G Remington, J Lee, O Agid, H Takeuchi, G Foussias, M Hahn, G Fervaha, L Burton, V Powel. Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert opinion on drug safety. vol 15. issue 9. 2017-02-27. PMID:27207070. |
clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use. |
2017-02-27 |
2023-08-13 |
Not clear |
| Mugtaba Osman, Vekneswaran Devada. Clozapine-induced dysphagia with secondary substantial weight loss. BMJ case reports. vol 2016. 2017-02-27. PMID:27543610. |
an 18-year-old single man with an established diagnosis of treatment-resistant paranoid schizophrenia recovered well on a therapeutic dose of clozapine. |
2017-02-27 |
2023-08-13 |
Not clear |
| Peter Manu, Eugene Grudnikof. Clozapine for Treatment-Resistant Schizophrenia. American journal of therapeutics. vol 23. issue 5. 2017-02-27. PMID:27603450. |
clozapine for treatment-resistant schizophrenia. |
2017-02-27 |
2023-08-13 |
Not clear |
| Tarun Bastiampillai, Arun Gupta, Stephen Alliso. FDA changes clozapine monitoring guidelines: Implications for worldwide practice. Asian journal of psychiatry. vol 21. 2017-02-13. PMID:27208449. |
these changes will allow a greater number of patients with schizophrenia in usa to be continued on clozapine. |
2017-02-13 |
2023-08-13 |
Not clear |
| Michiko Fujimoto, Ryota Hashimoto, Hidenaga Yamamori, Yuka Yasuda, Kazutaka Ohi, Hirotsugu Iwatani, Yoshitaka Isaka, Masatoshi Taked. Clozapine improved the syndrome of inappropriate antidiuretic hormone secretion in a patient with treatment-resistant schizophrenia. Psychiatry and clinical neurosciences. vol 70. issue 10. 2017-02-13. PMID:27539233. |
clozapine improved the syndrome of inappropriate antidiuretic hormone secretion in a patient with treatment-resistant schizophrenia. |
2017-02-13 |
2023-08-13 |
Not clear |
| Antonio Bruno, Gianluca Pandolfo, Manuela Crucitti, Simona Lorusso, Rocco Antonio Zoccali, Maria Rosaria Anna Muscatell. Acetyl-L-Carnitine Augmentation of Clozapine in Partial-Responder Schizophrenia: A 12-Week, Open-Label Uncontrolled Preliminary Study. Clinical neuropharmacology. vol 39. issue 6. 2017-01-23. PMID:27404738. |
acetyl-l-carnitine augmentation of clozapine in partial-responder schizophrenia: a 12-week, open-label uncontrolled preliminary study. |
2017-01-23 |
2023-08-13 |
Not clear |
| Antonio Bruno, Gianluca Pandolfo, Manuela Crucitti, Simona Lorusso, Rocco Antonio Zoccali, Maria Rosaria Anna Muscatell. Acetyl-L-Carnitine Augmentation of Clozapine in Partial-Responder Schizophrenia: A 12-Week, Open-Label Uncontrolled Preliminary Study. Clinical neuropharmacology. vol 39. issue 6. 2017-01-23. PMID:27404738. |
this was the first 12-week, open-label, uncontrolled trial aimed at exploring the efficacy of acetyl-l-carnitine (alc) add-on pharmacotherapy on clinical symptoms and cognitive functioning in 15 schizophrenia patients with suboptimal clinical response despite receiving clozapine (clz) monotherapy at the highest tolerated dosage. |
2017-01-23 |
2023-08-13 |
Not clear |
| Junji Gon, Yasushi Takehisa, Yuji Yada, Yoshiki Kishi, Etsuko Oshima, Yukitoshi Takahashi, Manabu Takak. Encephalitis With Antibodies to GluN2B During Administration of Clozapine. Clinical neuropharmacology. vol 39. issue 6. 2017-01-23. PMID:27482955. |
clozapine's immunomodulatory properties may contribute to its effect on schizophrenia as well as various adverse effects. |
2017-01-23 |
2023-08-13 |
Not clear |
| Junji Gon, Yasushi Takehisa, Yuji Yada, Yoshiki Kishi, Etsuko Oshima, Yukitoshi Takahashi, Manabu Takak. Encephalitis With Antibodies to GluN2B During Administration of Clozapine. Clinical neuropharmacology. vol 39. issue 6. 2017-01-23. PMID:27482955. |
we experienced a patient who developed refractory schizophrenia that mimicked an exacerbation of encephalitis with antibodies to n-methyl-d-aspartate-type glutamate receptor (glun2b) after administration of clozapine for 26 days. |
2017-01-23 |
2023-08-13 |
Not clear |
| Junji Gon, Yasushi Takehisa, Yuji Yada, Yoshiki Kishi, Etsuko Oshima, Yukitoshi Takahashi, Manabu Takak. Encephalitis With Antibodies to GluN2B During Administration of Clozapine. Clinical neuropharmacology. vol 39. issue 6. 2017-01-23. PMID:27482955. |
when we administer clozapine to patients with refractory schizophrenia, we should be careful to differentiate between a diagnosis of refractory schizophrenia and encephalitis with antibodies to glun2b. |
2017-01-23 |
2023-08-13 |
Not clear |
| Jay Carruthers, Marleen Radigan, Matthew D Erlich, Gyojeong Gu, Rui Wang, Eric Y Frimpong, Susan M Essock, Mark Olfson, Enrico G Castillo, Gregory A Miller, Lloyd I Sederer, T Scott Strou. An Initiative to Improve Clozapine Prescribing in New York State. Psychiatric services (Washington, D.C.). vol 67. issue 4. 2017-01-17. PMID:26725299. |
clozapine remains the only medication approved for treatment-resistant schizophrenia. |
2017-01-17 |
2023-08-13 |
Not clear |